Latest Breaking News On - Updated results from - Page 1 : comparemela.com

Genmab A/S: Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Genmab A/S: Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesEpcoritamab monotherapyEpcoritamab polatuzumab vedotinJudith klimovskyAndrew carlsenDavid freundelRituximab lenalidomideAccess libraryOutcomes researchProduct communicationsClinical researchA survey of healthcare professionalsGenmab us incPharmacokinetic translational researchExchange commission

Genmab to Present New and Updated Results From Multiple

Genmab to Present New and Updated Results From Multiple
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesEpcoritamab monotherapyJudith klimovskyPolatuzumab vedotinAndrew carlsenDavid freundelA survey of healthcare professionalsOutcomes researchClinical researchAccess libraryEuropean hematology associationExchange commissionPharmacokinetic translational researchProduct communicationsAbbvie biotechnology ltd

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesDavid freundelAndrew carlsenPolatuzumab vedotinEpcoritamab monotherapyJudith klimovskyCurtain raiser pressProduct communicationsPharmacokinetic translational researchAbbvie biotechnology ltdExchange commissionOutcomes researchA survey of healthcare professionalsAccess libraryEuropean hematology association

Overall Survival Improved with Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

1. The 5-year overall survival had a hazard ratio of 0.49, and this benefit was generally consistent across subgroups (stage, EGFR mutation, race) as well as adjuvant chemotherapy status 2. Safety was consistent with prior analysis and no new adverse events were reported. Evidence Rating Level: 1 (Excellent) Study Rundown: Resectable non-small cell lung cancer

Padjuvant osimertinibRating levelMutated stageSmall cell lung cancerUpdated results from

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomNew jerseyMehdi hamadaniLoncastuximab tesirinePaolof caimiMohamed zakiParco cianiEugenia litzMary ann ondishKathryna logronioLausanne biopJohn wileyEuropean hematology associationExchange commission